Next Science Limited announced that its proprietary XPERIENCETM Surgical Solution has been cleared by Australia's Therapeutic Goods Administration (TGA). The TGA clearance allows for the sale of XPERIENCETM in Australia. XPerienceTM is designed for use in virtually every open surgical procedure as a single step (no wash out) application where the residual solution remains in the surgical site after closure. The continued presence of XPERIENCE will help to defend against pathogens for several hours, giving surgeons a simple and effective adjunct to help prevent surgical site and post-operative infections. XPERIENCETM is currently sold in the US market where the product received a 510(k) clearance from the US Food and Drug Administration (FDA) in April this year. The initial sales focus for XPERIENCETM in the US has been the orthopaedic and plastic and reconstructive surgery markets (the latter, through our recently signed distribution agreement with TELA Bio Inc).